[ET Net News Agency, 20 August 2019] WuXi Biologics (Cayman) Inc. (02269) said its
profit attributable to equity shareholders of the company was RMB450 million for the six
months ended 30 June 2019, a year-on-year increase of 80.3%. The basic earnings per share
were RMB0.37. No dividend will be distributed.
The revenue was RMB1,607.1 million, a year-on-year increase of 52.4%. The gross profit
was RMB671 million, a year-on-year increase of 61.8%. (RC)